Skip to main
AIM
AIM logo

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. has demonstrated a strong positive outlook due to encouraging data from multiple studies, particularly highlighting Ampligen's efficacy in diverse therapeutic areas, including colorectal cancer and post-COVID conditions. The company's recent announcements of positive initial data from its Phase 2a study for colorectal cancer and the Phase 2 study for post-COVID conditions signify potential catalysts for future growth and enhanced investor confidence. The continued progress in research and development of its flagship product, Ampligen, positions AIM ImmunoTech favorably in the market focused on addressing unmet medical needs in cancer and viral diseases.

Bears say

AIM ImmunoTech Inc reported a net loss of $2.8 million, translating to an earnings per share (EPS) of $(3.68), which underperformed against earlier estimates of $(8.00). The company's outlook is hindered by significant risks, including balance sheet and liquidity challenges, potential failures in demonstrating safety and efficacy during clinical trials, and obstacles in securing regulatory approvals. Additional concerns stem from commercialization hurdles, reimbursement issues, competition, and broader macroeconomic factors impacting investor sentiment towards biotech stocks.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Nov 6, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.